At a glance
ClinicalIndex Comparison RecordN/ACompleted· 534 enrolled
Drug / intervention
Pregabalindrug
Likely dose
Pregabalin 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SPECIAL INVESTIGATION OF PREGABALIN FOR FIBROMYALGIA
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Jan 23, 2013·Updated Oct 10, 2023
In Brief
An observational study evaluating Pregabalin for Pain Associated With Fibromyalgia. Completed, enrolled 534 participants.
Detailed Summary
To collect the efficacy and safety information of Pregabalin on Fibromyalgia patients related to their appropriate use in daily practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPain Associated With Fibromyalgia
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartFeb 2013
Primary CompletionJul 2017
TodayJul 2026
First PostedJan 23, 2013
Enrollment StartFeb 1, 2013
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.4 years ago
Interventions
Pregabalindrug
The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.